X

Drug Profile

HLX 99

Alternative Names: HLX-99

Latest Information Update: 10 May 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Henlius Biotech
Class Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

02 May 2024 Preclinical trials in Amyotrophic lateral sclerosis in China (PO) (Shanghai Henlius Biotech pipeline, May 2024)
02 May 2024 Shanghai Henlius Biotech expects approval of IND application of HLX 99 for Amyotrophic lateral sclerosis in first half of 2024
31 Mar 2024 Henlius has patent filed for HLX 99

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com